[1]王俊慧a,宋　爽b,王德平.血清 IGF-1和 IGFBP-3水平检测在评价基因重组人生长激素治疗特发性身材矮小儿童的疗效分析[J].现代检验医学杂志,2019,34(06):105-108.[doi:10.3969 ／ j.issn.1671-7414.2019.06.026]
　WANG Jun-huia,SONG Shuangb,WANG De-ping.Effects of Recombinant Human Growth Hormone on Serum IGF-1 and IGFBP-3 in Children with Adolescent and Late Adolescent Idiopathic Short Stature[J].Journal of Modern Laboratory Medicine,2019,34(06):105-108.[doi:10.3969 ／ j.issn.1671-7414.2019.06.026]
点击复制

血清 IGF-1和 IGFBP-3水平检测在评价基因重组人生长激素治疗特发性身材矮小儿童的疗效分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
105-108
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Effects of Recombinant Human Growth Hormone on Serum IGF-1 and IGFBP-3 in Children with Adolescent and Late Adolescent Idiopathic Short Stature
文章编号:
1671-7414（2019）06-105-04
作者:
王俊慧1a; 宋　爽1b; 王德平2
（1. 辽宁省健康产业集团铁煤总医院a. 内分泌科；b. 神经内二科，辽宁铁岭　112700；3. 黑龙江省牡丹江医学院 附属红旗医院内分泌科，黑龙江牡丹江　157100）
Author(s):
WANG Jun-hui1a;  SONG Shuang1b;  WANG De-ping2
（1a. Department of Endocrinology, 1b. the Secend Department of Neurology, Liaoning Provincial Health Industry Group Iron and Coal General Hospital，Liaoning Tieling 112700, China; 2. Department of Endocrinology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang Mudanjiang 157011,China）
关键词:
重组人生长激素; 未青春发育; 青春发育后期; 特发性身材矮小; 疗效
分类号:
R179；R392.11
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.026
文献标志码:
A
摘要:
目的　探讨基因重组人生长激素治疗未青春发育及青春发育后期特发性身材矮小(idiopathic short stature， ISS) 儿童血清胰岛素样生长因子-1（IGF-1）和胰岛素样生长因子结合蛋白-3（IGFBP-3）水平及临床疗效的影响。方 法　回顾性分析2016 年4 月～ 2018 年4 月期间在辽宁省健康产业集团铁煤总医院和黑龙江省牡丹江医学院附属红旗 医院接受治疗的40 例未青春发育及青春发育后期ISS 儿童的临床资料。25 例接受为期6 个月的基因重组人生长激素治 疗的儿童纳入观察组，余15 例未接受任何药物治疗的儿童纳入对照组，接受6 个月的观察。比较两组儿童治疗前和治 疗6 个月后体重、身高、生长速度（GV）、骨龄（BA）、预测成年身高（FAH）以及IGF-1 和IGFBP-3 水平变化， 记录观察组患儿治疗期间不良反应发生情况。结果　经过治疗观察组GV（3.49±1.37cm/ 年 vs 2.15±0.48 cm/ 年）和 FAH（151.05±3.67 cm vs 145.89±3.51 cm）以及血清IGF-1（395.49±103.58ng/ml vs 204.26±45.47 ng/ml）和IGFBP-3 （5 012.71±1 126.72 ng/ml vs 3 125.68±1 125.63 ng/ml）水平均较治疗前显著增加（t =4.615，5.074，8.452，5.924，均 P <0.01），且显著大于对照组（t =3.331，4.165，5.902，5.307，均P <0.01），两组治疗后BA比较差异无统计学意义（t =0.067， P >0.05）。对照组治疗前和治疗后BA，GV 和FAH 以及血清IGF-1 和IGFBP-3 水平比较差异无统计学意义（P >0.05）。 观察组1 例发生月经周期延长1 次；1 例膝关节痛，补充钙制剂后好转。结论　基因重组人生长激素治疗未青春发育和 青春发育后期ISS 儿童疗效确切，安全性高，可通过血清IGF-1 及IGFBP-3 水平监测来评估治疗效果。
Abstract:
Objective　To investigate the effect of recombinant human growth hormone (rhGH) on serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels and clinical efficacy in children with idiopathic short stature (ISS) during adolescence and late adolescence. Methods　The clinical data of 40 children with ISS who were not puberty and puberty in Liaonin Provincial Health Industry Group Iron and Coal General Hospital and Hongqi Hospital Affiliated to Mudanjiang Medical University from April 2016 to April 2018 were retrospectively analyzed. Twenty-five children who received 6 months of recombinant human growth hormone therapy were enrolled in the observation group, and the remaining 15 children who did not receive any drug treatment were included in the control group for 6 months. Body weight, height, growth rate (GV), bone age (BA), predicted adult height (FAH), and serum IGF-1 and IGFBP-3 were compared between the two groups before and after 6 months of treatment. The incidence of adverse reactions during treatment was recorded in the observation group. Results　The levels of GV （3.49±1.37cm/year vs 2.15±0.48 cm/year）and FAH（151.05±3.67 cm vs 145.89±3.51 cm） and serum IGF-1 （395.49±103.58ng/ml vs 204.26±45.47 ng/ml） and IGFBP-3 （5 012.71±1 126.72 ng/ml vs 3 125.68±1 125.63 ng/ml） in the treatment group were significantly higher than those before treatment （t =4.615， 5.074，8.452，5.924，all P <0.01）, and significantly higher than those in the control group （t =3.331，4.165，5.902，5.307， all P <0.01），There were no significant differences in BA （t =0.067，P >0.05）. GV and FAH and serum IGF-1，IGFBP-3 levels before and after treatment in the control group (P >0.05). One case of the observation group occurred one time of menstrual cycle extension and one case of knee joint pain, improved after calcium supplementation. Conclusion　rhGH is effective and safe in the treatment of ISS children in adolescence and late adolescence. The therapeutic effect can be evaluated by monitoring the levels of serum IGF-1 and IGFBP-3.

参考文献/References:

[1]　DATEKI S, NAKATOMI A, WATANABE S, et al. Identification of a novel heterozygous mutation of the Aggrecan gene in a family with idiopathic short stature and multiple intervertebral disc herniation.[J]. Journal of Human Genetics, 2017, 62(7):717-721.
[2]　何英, 柳开典, 袁作芬, 等. 重组人生长激素对 GHD 和ISS 患儿的临床影响[J]. 中国妇幼健康研究, 2017, 28(10): 1281-1283. HE Ying, LIU Kaidian, YUAN Zuofen, et al. Influence of recombinant human growth hormone on children with growth hormone deficiency or idiopathic short stature [J]. Chinese Journal of Woman and Child Health Research, 2017, 28(10): 1281-1283.
[3]　张本金, 吕有道, 邓春晖. 不同剂量重组人生长激素 治疗青春期前ISS 患者的临床疗效分析[J]. 重庆医 学, 2016, 45(6):813-815. ZHANG Benjin, LU¨ Youdao, DENG Chunhui. Clinical efficacy of different doses of recombinant human growth hormone in the treatment of pre-adolescent ISS [J]. Chongqing Medicine, 2016, 45(6):813-815.
[4]　STAWERSKA R, CZKWIANIANC E, SMYCZY?SKA J, et al. Nutritional status in short stature children is related to both ghrelin and Insulin-like growth factor I concentrations[J]. Journal of Pediatric Gastroenterology & Nutrition, 2016, 64(5):1,812-817.
[5]　李辉, 季成叶, 宗心南, 等. 中国0 ～ 18 岁儿童、青 少年身高、体重的标准化生长曲线[J]. 中华儿科杂 志, 2009, 47(7):487-492. LI Hui, JI Chengye, ZONG Xinnan, et al. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years [J]. Chinese Journal of Pediatrics, 2009, 47(7):487-492.
[6]　陈龙, 陈晓青. 特发性矮身材儿童生长障碍与GHIGF1 轴关系的研究进展[J]. 临床合理用药杂志, 2016, 9(44):179-181. CHEN Long, CHEN Xiaoqing. Research progress on the relationship between growth disorder and GH-IGF1 axis in children with idiopathic short stature[J]. Chinese Journal of Clinical Rational Drug Use, 2016, 9(44): 179-181.
[7]　SAENGER P. Ten years of biosimilar recombinant human growth hormone in Europe:[J]. Drug Design Development & Therapy, 2017, 11:1505-1507.
[8]　李想, 乐原. 基因重组人生长激素治疗特发性矮小症 患儿的临床疗效及安全性研究[J]. 锦州医科大学学 报, 2018, 39(2):20-22. LI Xiang, LE Yuan. Clinical effect and safety of rhGH in treating children with idiopathic short stature[J]. Journal of Jinzhou Medical University, 2018, 39(2):20-22.
[9]　REN Shanxiang, NIE Yuxiang, WANG Aihong. Effects of recombinant human growth hormone in the treatment of dwarfism and relationship between IGF-1, IGFBP-3 and thyroid hormone[J]. Experimental & Therapeutic Medicine, 2016, 12(6):3579-3582.
[10] PENG Ping, MA Chunling, WAN Shumei, et al. Inhibition of p53 relieves insulin resistance in fetal growth restriction mice with catch-up growth via activating IGFBP3/IGF-1/IRS-1/Akt signaling pathway[J]. Journal of Nanoscience & Nanotechnology, 2018, 18(6):3925-3935.
[11] 张宇, 李温慈, 应克伟, 等. IGF-1 与IGFBP-3 在未 青春发育特发性矮小儿童生长激素治疗中的意义 [J]. 中国现代医生, 2013, 51(33):50-52. ZHANG Yu, LI Wenci, YING Kewei, et al. The significance of IGF-1 and IGFBP-3 in growth hormonetherapy of idiopathic short stature in prepuberty[J]. China Modern Doctor, 2013, 51(33): 50- 52.

备注/Memo

备注/Memo:
基金项目：牡丹江市科学技术计划项目（Z2018S068）。 作者简介：王俊慧（1984-），女，本科，主治医师，研究方向：内分泌，E-mail:65399823@qq.com。 通讯作者：王德平（1986-），男，硕士，主治医师，研究方向：内分泌学。 收稿日期：2019-06-24　
更新日期/Last Update: 2019-12-25